Podcast
Author(s):
In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
Durvalumab plus BCG significantly improves DFS in NMIBC
Physical function and frailty measures offer distinct insights in patients with bladder cancer
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test
Combination therapy linked to longer OS vs ADT in veterans with mHSPC